↓
★★★Well replicated — this finding’s sources average out to meta-analyses, systematic reviews or high-powered trials.
The loss did not creep back over a second year
Across 104 weeks, 152 adults on 2.4 mg weekly sat 15.2% below their starting weight, against 2.6% on placebo. Nobody was followed after the last injection.
What the study found
Two years in, the loss held at 15.2% rather than creeping back
Weight-loss drugs are usually accused of a plateau that unravels. Across 104 weeks, 152 adults on 2.4mg weekly semaglutide sat 15.2% below their starting weight against 2.6% on placebo, and 77.1% were still at least 5% down, against 34.4%.
The caveat · Small for a phase 3 trial
Three hundred and four people is small for a phase 3 trial, and 93% were white and 78% women. Gastrointestinal effects, mostly mild, reached 82.2% against 53.9% on placebo. Nobody was followed after the last injection, so this describes two years on the drug rather than two years of results.